YaoGeJu

Company directoryChina company filings

Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference e6b511976b

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

27 acceptance records as first applicant, grouped into 10 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Esomeprazole Sodium for Injection 4 records · Latest accepted 2026/07/03

Supplement · 2Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2601259Supplement2026/07/03Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2601258Supplement2026/07/03Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHS2201987Generic2022/11/15Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHS2201985Generic2022/11/15Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Doxycycline Hyclate for Injection 2 records · Latest accepted 2026/01/31

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600321Generic2026/01/31Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHS2600319Generic2026/01/31Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
拉考沙胺颗粒 · No verified English name 1 records · Latest accepted 2025/09/11

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503370Generic2025/09/11Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
注射用甲苯磺酸奥马环素 · No verified English name 1 records · Latest accepted 2025/08/25

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2503111Generic2025/08/25Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Isavuconazonium Sulfate for Injection 1 records · Latest accepted 2024/08/02

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402455Generic2024/08/02Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Lornoxicam for Injection 1 records · Latest accepted 2024/03/23

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400902Generic2024/03/23Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Roxatidine Acetate Hydrochloride For Injection 1 records · Latest accepted 2023/12/26

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2303622Generic2023/12/26Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for Injection 8 records · Latest accepted 2023/12/09

Supplement · 8

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2302700Supplement2023/12/09Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2302699Supplement2023/12/09Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2302698Supplement2023/12/09Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2302697Supplement2023/12/09Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2151014Supplement2021/11/16Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2151013Supplement2021/11/16Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2151012Supplement2021/11/16Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2151011Supplement2021/11/16Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Amoxicillin Sodium and Clavulanate Potassium for Injection 6 records · Latest accepted 2023/07/04

Supplement · 6

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2301485Supplement2023/07/04Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2301484Supplement2023/07/04Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2301483Supplement2023/07/04Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2250040Supplement2022/01/17Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2150649Supplement2021/06/07Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2150648Supplement2021/06/07Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Sulbactam Sodium For Injection 2 records · Latest accepted 2022/10/25

Supplement · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2201955Supplement2022/10/25Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
CYHB2201954Supplement2022/10/25Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Doxycycline Hyclate for Injection CYHS2600321Generic2026/01/31Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
Doxycycline Hyclate for Injection CYHS2600319Generic2026/01/31Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
拉考沙胺颗粒 · No verified English name CYHS2503370Generic2025/09/11Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized; Huayi Pharmaceuticals (Anhui) Co., Ltd.CDE ↗
注射用甲苯磺酸奥马环素 · No verified English name CYHS2503111Generic2025/08/25Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗

Catalogue holder records

12 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Lornoxicam for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202542382025/05/20Generic approved under the new chemical-drug registration classificationCDE ↗
Roxatidine Acetate Hydrochloride For InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202540222025/04/30Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202441432024/06/25Generic approved under the new chemical-drug registration classificationCDE ↗
Esomeprazole Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202441442024/06/25Generic approved under the new chemical-drug registration classificationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H200559332023/01/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202370092023/01/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202370082023/01/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Cefoperazone Sodium and Sulbactam Sodium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202370102023/01/28Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Amoxicillin Sodium and Clavulanate Potassium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H202270942022/07/21Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Amoxicillin Sodium and Clavulanate Potassium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H200593752022/03/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Amoxicillin Sodium and Clavulanate Potassium for InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H200593742022/03/25Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Pantoprazole Sodium For InjectionHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanized国药准字H200839102021/11/19Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

8 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
阿洛西林钠 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20190006573A2024/11/15CDE ↗
硫酸头孢匹罗 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20190005769A—CDE ↗
美洛西林钠 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20190005768A—CDE ↗
头孢替唑钠 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20190001239A2024/11/15CDE ↗
依达拉奉 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20180001720A2024/11/15CDE ↗
维生素K1 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20170001286I—CDE ↗
埃索美拉唑钠 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20170000646I—CDE ↗
盐酸法舒地尔 · No verified English nameHainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedY20170000451I—CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

4 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
注射用盐酸氨溴索 · No verified English name CYHB2402022Supplement2024/11/30Sheng Jia (Bin Hai) Biopharmaceuticals Technology Co., Ltd. romanized; Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
注射用盐酸氨溴索 · No verified English name CYHB2402021Supplement2024/11/30Sheng Jia (Bin Hai) Biopharmaceuticals Technology Co., Ltd. romanized; Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
注射用替卡西林钠克拉维酸钾 · No verified English name CYHB2302226Supplement2023/10/10Zhuhai You Run Pharmaceuticals Technology Co., Ltd. romanized; Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗
注射用替卡西林钠克拉维酸钾 · No verified English name CYHB2302225Supplement2023/10/10Zhuhai You Run Pharmaceuticals Technology Co., Ltd. romanized; Hainan Wei Kang Pharmaceutical (Qian Shan) Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.